Celltrion’s COVID-19 Treatment Regdanvimab Is Approved In Korea
Follows Conditional Approval In February From Korean Regulator
Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.
You may also be interested in...
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.